Article
Rochester, MN-When Mayo Clinic researchers recently reported a link between nonsteroidal anti-inflammatory drugs (NSAIDs) and a reduced incidence of prostate cancer, it simply confirmed what many in the field already suspected.
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC